BIOMAT Database Logo BIOMAT Database Logo

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. 2020

Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007968 Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7) Encephalitis, JC Polyomavirus,Progressive Multifocal Leukoencephalopathy,JC Polyomavirus Encephalopathy,Encephalopathies, JC Polyomavirus,Encephalopathy, JC Polyomavirus,JC Polyomavirus Encephalitis,Leukoencephalopathies, Progressive Multifocal,Multifocal Leukoencephalopathies, Progressive,Multifocal Leukoencephalopathy, Progressive,Progressive Multifocal Leukoencephalopathies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.
April 2022, Journal of neurovirology,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
April 2019, The New England journal of medicine,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
April 2019, The New England journal of medicine,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
July 2021, Neurology(R) neuroimmunology & neuroinflammation,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab Treatment.
July 2020, The Neurohospitalist,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.
November 2019, Neurology(R) neuroimmunology & neuroinflammation,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China.
December 2023, Journal of neurovirology,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV.
May 2022, Viruses,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy.
January 2021, Therapeutic advances in neurological disorders,
Christoph Mahler, and Michael Andrews, and Sian M Henson, and Sharmilee Gnanapavan
Successful treatment of HIV-associated progressive multifocal leukoencephalopathy with pembrolizumab.
March 2022, AIDS (London, England),
Copied contents to your clipboard!